BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia

Annals of Hematology

Volumn 88, Issue 4, 2009, Pages 333-340

  Bhattacharyya, Joyeeta ^a   Mihara, Keichiro ^a   Yasunaga, Shin'ichiro ^a   Tanaka, Hideo ^a   Hoshi, Masaharu ^a   Takihara, Yoshihiro ^a   Kimura, Akiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

BCR ABL; BMI 1; CML; Posttranscriptional regulation

Indexed keywords

BCR ABL PROTEIN; BMI1 PROTEIN; MESSENGER RNA;

ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CANCER GROWTH; CD34+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE MARKER; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSCRIPTION REGULATION; UBIQUITINATION; WESTERN BLOTTING;

ANTIGENS, CD34; BLAST CRISIS; CELL LINE, TUMOR; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; TRANSCRIPTION, GENETIC;

EID: 60749115380     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0603-8     Document Type: Article

References (26)

1. Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, doi: 10.1038/nm0596-561
2. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, doi: 10.1056/NEJM200104053441401
3. Park IK, Qian D, Kie M et al (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302-305, doi: 10.1038/nature01587
4. Dick JE (2003) Stem cells: Self-renewal writ in blood. Nature 423:231-233, doi: 10.1038/423231a
5. Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255-260, doi: 10.1038/nature01572
6. Iwama A, Oguro H, Negishi M et al (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21:843-851, doi: 10.1016/j.immuni.2004.11.004
7. Mihara K, Chowdhury M, Nakaju N et al (2006) Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 107:305-308, doi: 10.1182/blood-2005-06-2393
8. Mihara K, Takihara Y, Kimura A (2007) Genetic and epigenetic alterations in myelodysplastic syndrome. Cytogenet Genome Res 118:297-303, doi: 10.1159/000108313
9. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A (2007) Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 21:1116-1122
10. Cuenco GM, Ren R (2001) Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 20:8236-8248, doi: 10.1038/sj.onc.1205095
11. Perrotti D, Cesi V, Trotta R et al (2002) BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30:48-58, doi: 10.1038/ng791
12. Wagner K, Zhang P, Rosenbauer F et al (2006) Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A 103:6338-6343, doi: 10.1073/pnas.0508143103
13. Ferrari-Amorotti G, Keeshan K, Zattoni M et al (2006) Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. Blood 108:1353-1362, doi: 10.1182/blood-2006-01-011833
14. Guerzoni C, Bardini M, Mariani SA et al (2006) Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 107:4080-4089, doi: 10.1182/blood-2005-08-3181
15. Nagy E, Beck Z, Kiss A et al (2003) Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer 39:2298-2305, doi: 10.1016/S0959-8049(03)00552-5
16. Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7:441-453, doi: 10.1038/nrc2147
17. Kramer A, Loffler H, Bergmann J, Hochhaus A, Hehlmann R (2001) Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia. Leukemia 15:62-68, doi: 10.1038/sj.leu.2402005
18. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204-2205, doi: 10.1182/blood-2004-04-1335
19. Mauro MJ, Druker BJ, Maziarz RT (2004) Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28(Suppl 1):S71-S73, doi: 10.1016/ j.leukres.2003.10.017
20. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979-981
21. Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, doi: 10.1182/blood-2006-03-011239
22. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV (2007) The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110:380-383, doi: 10.1182/ blood-2006-12-065599
23. van der Lugt NM, Domen J, Linders K et al (1994) Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8:757-769, doi: 10.1101/gad.8.7.757
24. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168, doi: 10.1038/ 16476
25. Li Z, Cao R, Wang M, Myers MP, Zhang Y, Xu RM (2006) Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem 281:20643-20649, doi: 10.1074/jbc.M602461200
26. Ben-Saadon R, Zaaroor D, Ziv T, Ciechanover A (2006) The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell 24:701-711, doi: 10.1016/j.molcel.2006.10.022